Association of Myeloperoxidase G-463A gene polymorphism with diabetic nephropathy in Japanese type 2 diabetic subjects

Endocrine Journal

Volumn 60, Issue 4, 2013, Pages 457-471

  Katakami, Naoto ^a   Kume, Shinji ^b   Kaneto, Hideaki ^a   Uzu, Takashi ^b   Kashiwagi, Atsunori ^b   Yamasaki, Yoshimitsu ^a   Maegawa, Hiroshi ^b   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Diabetes; Myeloperoxidase; Nephropathy; Polymorphism; Single nucleotide polymorphisms (SNP)

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GENOMIC DNA; MESSENGER RNA; MYELOPEROXIDASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; JAPANESE; LIPID DIET; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MOUSE; MPO GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; PROTEIN EXPRESSION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

3' FLANKING REGION; AGED; ALBUMINURIA; ANIMALS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JAPAN; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PEROXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 84876990486     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Klebanoff SJ (1980) Oxygen metabolism and the toxic cproperties of phagocytes. Ann Intern Med 93: 480-489.
2. Daugherty A, Dunn JL, Rateri DL, Heinecke JW (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94: 437-444.
3. Zhang R, Brennan ML, Shen Z, McPherson JC, Schmitt D, et al. (2002) Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 277: 46116-46122.
4. Podrez EA, Abu-Soud HM, Hazen SL (2000) Myeloperoxidase generated oxidants and atherosclerosis. Free Radic Biol Med 28: 1717-1725.
5. Zhang R, Shen Z, Nauseef WM, Hazen SL (2002) Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase-deficient subjects: systematic identification of multiple endogenous diffusible substrates for Myeloperoxidase in plasma. Blood 99: 1802-1810.
6. Malle E, Buch T, Grone HJ (2003) Myeloperoxidase in kidney disease. Kidney Int 64: 1956-1967.
7. Odobasic D, Kitching AR, Semple TJ, Holdsworth SR (2007) Endogenous myeloperoxidase promotes neutrophilmediated renal injury, but attenuates T cell immunity inducing crescentic glomerulonephritis. J Am Soc Nephrol 18: 760-770.
8. Grone HJ, Grone EF, Malle E (2002) Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis. Lab Invest 82: 5-14.
9. Matthijsen RA, Huugen D, Hoebers NT, deVries B, Peutz-Kootstra CJ, et al. (2007) Myeloperoxidase is critically involved in the induction of organ damage after renal ischemia reperfusion. Am J Pathol 171: 1743-1752.
10. Ha H, Lee HB (2001) Oxidative stress in diabetic nephropathy: basic and clinical information. Curr Diab Rep 1: 282-287.
11. Kitada M, Koya D, Sugimoto T, Isono M, Araki S, et al. (2003) Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 52: 2603-2614.
12. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS (2002) Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 61: 186-194.
13. Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, et al. (2005) Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67: 1890-1898.
14. Piedrafita FJ, Molander RB, Vansant G, Orlova EA,Pfhal M, et al. (1996) An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271: 14412-14420.
15. Reynolds WF, Chang E, Douer E, Ball ED, Kanda V (1997) An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 90: 2730-2737.
16. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus (2010) Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 1: 212-228.
17. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992.
18. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, et al. (2002) Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 347: 1916-1923.
19. Tanaka Y, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, et al. (2011) Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int 79: 871-882.
20. Risdon RA, Sloper JC, De Wardener HE (1968) Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2(7564): 363-366.
21. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA (2001) A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 142: 336-339.
22. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio RA (2004) Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 116: 429-430.
23. Anderson MM, Requenta JR, Crowley JR, Thorpe SR, Heinecke JW (1999) The myeloperoxidase system of human phagocytes generates Ne-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104:103-113.
24. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, et al. (1997) Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100: 2995-3004.
25. Augustin AJ, Spitznas M, Koch F, Grus F, Bocker T (1995) Indicators of oxidative tissue damage and inflammatory activity in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ger J Ophthalmol 4: 47-51.